Skip to main content

TXG

Stock

TXG

Stock
Health Care
Health Information Services

Performance overview

TXG Price
Price Chart

Forward-looking statistics

Beta
1.65
Risk
68.22%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Company info

SectorHealth Care
IndustryHealth Information Services
Employees2K
Market cap$2.6B

Fundamentals

Enterprise value$1.1B
Revenue$624.7M
Revenue per employee—
Profit margin-25.14%
Debt to equity11.33

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.30
Dividend per share—
Revenue per share$5.15
Avg trading volume (30 day)$53M
Avg trading volume (10 day)$61M
Put-call ratio—

Macro factor sensitivity

Growth-2.9
Credit+5.8
Liquidity-0.6
Inflation-7.7
Commodities+0.0
Interest Rates-3.1

Valuation

Dividend yield0.00%
PEG Ratio-10.17
Price to sales2.45
P/E Ratio-10.17
Enterprise Value to Revenue1.73
Price to book2.16

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend day—

News

Wall Street Analysts Think 10x Genomics (TXG) Could Surge 43.12%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 43.1% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research (May 29, 2025)
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties

On Wednesday, 10x Genomics Inc TXG reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of $(0.30).

Benzinga (February 13, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free